Pectin-based nanomaterials as a universal polymer for type 2 diabetes management

Abstract

Type 2 diabetes mellitus (T2DM) is characterized by insufficient tissue insulin sensitivity, insufficient compensatory insulin secretory response, and insufficient insulin production by pancreatic islet cells, which account for more than 90% of all instances of diabetes mellitus, and defects in any of the mechanisms at play may cause a metabolic imbalance that results in the development of T2DM. By getting around several delivery limitations, nanomedicine can effectively increase the efficacy of oral drug administration. According to reports, nanostructures are absorbed 15–250 times more readily than microparticles. Furthermore, nanostructures are constantly used to maintain the release of drugs that are encapsulated to lower doses and dosage frequency, improving patient compliance and reducing adverse effects. Pectin is a biocompatible polysaccharide with a natural biological activity, which pectin in rats with type 2 diabetes was discovered to have potent hypoglycemic, antioxidant, immunomodulating, and anticancer properties that improved diabetic conditions and consequences, reduced insulin resistance, improved blood lipid levels, and reduced liver glycogen content, glucose tolerance, and glucose levels. As a result, the purpose of this article was to evaluate the background materials on the current condition of the scientific literature in this field of study and to review the employment feasibility as well as pectin-modified nanomaterial toward T2DM treatment because it has the ability to reduce insulin secretion and/or blood glucose levels following a sugar load.